drugset / Trial / NCT04612790

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

NCT04612790

Phase 3 Terminated 67 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

Timeline

Start
2021-03-31
Primary completion
2023-10-26
Completion
2023-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody Subcutaneous

Indications